APRE Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.

$4.95
As of 06/24/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/25/2005
Outstanding shares:  21,186,827
Average volume:  7,825,944
Market cap:   $102,332,374
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03836J102
ISIN:        US03836J1025
Sedol:      BKLG749
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   -0.06
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy